pp-015 Injection, pre-filled pen
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
Registered in
China
Comments
For primary hypercholesterolemia and mixed hyperlipidemia. Targets PCSK9 to reduce LDL cholesterol. Cardiovascular lipid-modifying agent, same class as evolocumab and alirocumab.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days